Compare FAMI & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAMI | GLMD |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 6.6M |
| IPO Year | 2018 | 2014 |
| Metric | FAMI | GLMD |
|---|---|---|
| Price | $1.44 | $0.80 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 600.1K | 82.7K |
| Earning Date | 08-04-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,831,754.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.11 | $0.73 |
| 52 Week High | $3.64 | $3.50 |
| Indicator | FAMI | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 42.18 |
| Support Level | $1.11 | $0.76 |
| Resistance Level | $1.43 | $0.88 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 79.09 | 54.60 |
Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.